Featured Publications
Buprenorphine uptake during pregnancy following the 2017 guidelines update on prenatal opioid use disorder
Nguemeni Tiako M, Meinhofer A, Friedman A, South E, Epstein R, Meisel Z, Morgan J. Buprenorphine uptake during pregnancy following the 2017 guidelines update on prenatal opioid use disorder. American Journal Of Obstetrics And Gynecology 2022, 227: 544-546.e1. PMID: 35613648, PMCID: PMC9420821, DOI: 10.1016/j.ajog.2022.05.041.Peer-Reviewed Original Research
2021
Predictors of Initiation of Medication for Opioid Use Disorder and Retention in Treatment Among U.S. Pregnant Women, 2013-2017.
Nguemeni Tiako MJ, Friedman A, Culhane J, South E, Meisel ZF. Predictors of Initiation of Medication for Opioid Use Disorder and Retention in Treatment Among U.S. Pregnant Women, 2013-2017. Obstetrics And Gynecology 2021, 137: 687-694. PMID: 33706349, DOI: 10.1097/aog.0000000000004307.Peer-Reviewed Original ResearchConceptsOpioid use disorderAdministration of medicationsPrimary opioid use disorderTreatment episodesPregnant womenMedication administrationUse disordersInitiation of methadoneCompletion of treatmentPredictors of initiationPrior treatment episodesCross-sectional analysisSecondary outcomesPrimary outcomeFindings highlight gapsCurrent guidelinesMedicationsSynthetic opioidsLogistic regressionAdministrationCare systemTreatmentWomenEpisodesMethadoneThe Government’s Involvement in Prenatal Drug Testing May Be Toxic
Nguemeni Tiako MJ, Sweeney L. The Government’s Involvement in Prenatal Drug Testing May Be Toxic. Maternal And Child Health Journal 2021, 26: 761-763. PMID: 33392931, DOI: 10.1007/s10995-020-03110-2.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersPregnant patientsSubstance useNon-pregnant peoplePrenatal drug testingNeonatal abstinence syndromePublic health scaleEvidence-based carePrenatal substance usePatient-provider relationshipReportable offenseWhite patientsBlack patientsAbstinence syndromeObstetric careChronic illnessGreater oddsHealthcare providersPatientsPregnant peopleHealthcare professionalsGreater riskRacial disparitiesDrug testing
2020
Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19
Nguemeni Tiako MJ. Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19. Journal Of Substance Use And Addiction Treatment 2020, 122: 108214. PMID: 33248862, PMCID: PMC7685132, DOI: 10.1016/j.jsat.2020.108214.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersTreatment optionsBuprenorphine accessPatient's homeCOVID-19Stark racial disparitiesRacial disparitiesConsiderable riskTelemedicine uptakeCommunity pharmaciesBuprenorphineMethadoneMedicationsSocioeconomic disparitiesPatientsDisordersRiskPre COVID-19DisparitiesHomeOptionsUptakeInconsistent Addiction Treatment for Patients Undergoing Cardiac Surgery for Injection Drug Use-associated Infective Endocarditis.
Nguemeni Tiako MJ, Hong S, Bin Mahmood SU, Mori M, Mangi A, Yun J, Juthani-Mehta M, Geirsson A. Inconsistent Addiction Treatment for Patients Undergoing Cardiac Surgery for Injection Drug Use-associated Infective Endocarditis. Journal Of Addiction Medicine 2020, 14: e350-e354. PMID: 32732685, DOI: 10.1097/adm.0000000000000710.Peer-Reviewed Original ResearchConceptsActive drug useInjection drug use-associated infective endocarditisOpioid use disorderPsychosocial consultationAddiction treatmentDrug rehabilitation programInfective endocarditisRehabilitation programUse disordersDrug use-associated infective endocarditisDrug useEvidence of enrollmentTertiary care centerInjection drug useUS opioid epidemicDrug rehabilitationRehabilitation attendanceMost patientsCardiac surgeryRetrospective reviewCare centerOpioid epidemicPatientsMedicationsIDUsGeographic Distribution of Medicaid-Claimant OB-GYNs Approved to Prescribe Buprenorphine for Opioid Use Disorder [15E]
Nguemeni Tiako M, Culhane J, Meisel Z. Geographic Distribution of Medicaid-Claimant OB-GYNs Approved to Prescribe Buprenorphine for Opioid Use Disorder [15E]. Obstetrics And Gynecology 2020, 135: 53s-53s. DOI: 10.1097/01.aog.0000663556.94003.be.Peer-Reviewed Original ResearchOpioid use disorderNeonatal abstinence syndromeOb-gynsUse disordersIncidence of NASHighest opioid overdose death ratesGuideline-recommended treatmentMaternal-fetal outcomesShorter hospital stayOpioid overdose death ratesU.S. opioid epidemicOverdose death ratesRural-Urban Continuum CodesUtero buprenorphine exposureNAS symptomsPrescribe BuprenorphinePrescribing barriersHospital stayBuprenorphine exposureMedicaid insuranceAbstinence syndromeOpioid epidemicBuprenorphine accessEffective treatmentHigh incidence